SRPT stock holds near USD 20 as analysts stay cautious

Sarepta Therapeutics stock (ISIN US8036071004) trades near USD 20 on September 18, 2026, while MarketBeat says the shares carry a consensus Hold rating and an average 12-month target of USD 25.6875. The stock sits with a market capitalization of USD 2.18 billion, and the gap to that target remains the main valuation marker for retail investors.

Analysts keep it in hold

According to MarketBeat on September 18, 2026, 20 brokerages covering Sarepta Therapeutics split into 6 sell, 5 hold and 9 buy ratings. The same report puts the average price target at USD 25.6875, which is 28.4 percent above a USD 20.00 reference price.

Benchmark reissued a sell rating on September 9, 2026, while Weiss Ratings upgraded the stock from sell (e+) to sell (d-) on September 8, 2026, according to the same MarketBeat item. The mix underlines a cautious sell-side stance rather than a broad reset to optimism.

Revenue beat sets the base

For the latest reported quarter, Yahoo Finance highlights Sarepta Therapeutics' Q2 earnings and revenues surpassing estimates. The same market page shows the stock at USD 19.95 in premarket trading on September 17, 2026, down 3.48 percent, which frames the current valuation against the latest reported operating run-rate.

That combination matters because the consensus target, the September 9 sell rating and the Q2 beat point to a stock that still divides analysts even after the latest numbers. For investors, the USD 25.6875 average target is the key near-term benchmark.

Near USD 20

SRPT stock last traded at USD 19.95 on September 17, 2026, before the current session on Nasdaq. With a market capitalization of USD 2.18 billion and a consensus target of USD 25.6875, the shares remain below where brokerages place the 12-month average case.

More news and analyses on Sarepta Therapeutics stock